1	Strength and durability of antibody responses to BNT162b2 and CoronaVac
2	
3	Benjamin J. Cowling ^{*1,2} , Irene O. L. Wong ^{*1} , Eunice Y. C. Shiu ¹ , Amber Y. T. Lai ¹ , Samuel
4	M. S. Cheng ¹ , Sara Chaothai ¹ , Kelvin K. H. Kwan ¹ , Mario Martín-Sánchez ¹ , Leo L. M.
5	Poon ^{1,3,4} , Dennis K. M. Ip ¹ , Gabriel M. Leung ^{1,2} , Nancy H. L. Leung ^{†1,2} , J. S. Malik
6	Peiris ^{†1,3,4}
7	
8	*Joint first authors with equal contribution
9	[†] Joint senior authors with equal contribution
10	
11	Affiliations:
12	1. WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of
13	Public Health, LKS Faculty of Medicine, The University of Hong Kong; Hong Kong Special
14	Administrative Region, China.
15	2. Laboratory of Data Discovery for Health; Hong Kong Science and Technology Park, Hong
16	Kong Special Administrative Region, China.
17	3. HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine,
18	The University of Hong Kong; Hong Kong Special Administrative Region, China.
19	4. Centre for Immunology and Infection; Hong Kong Science and Technology Park, Hong
20	Kong Special Administrative Region, China.
21	
22	Corresponding authors: N. Leung leungnan@hku.hk and B. Cowling, bcowling@hku.hk
23	Word count (abstract): 50
24	Word count (main text): 1819
25	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 ABSTRACT

- 27 We studied 2780 adults in Hong Kong who received CoronaVac inactivated virus vaccine
- 28 (Sinovac) and BNT162b2 mRNA vaccine ("Comirnaty", BioNTech/Fosun Pharma). We
- 29 found stronger and more durable antibody responses to two doses of the mRNA vaccine, and
- 30 slightly stronger initial antibody responses to each vaccine in younger adults and women.

INTRODUCTION 32

33	Vaccines for coronavirus disease 2019 (COVID-19) provide protection against infection and
34	can also ameliorate disease severity if breakthrough infections occur [1]. Protection against
35	infection is likely mediated through antibodies, and the effectiveness of different vaccine
36	technologies against mild symptomatic infection has been shown to correlate with the
37	strength of neutralizing antibody responses to those vaccines [2-4]. In particular, antibody
38	responses after receipt of inactivated COVID-19 vaccines have been shown to be somewhat
39	weaker than antibody responses to mRNA vaccines [5, 6], although T cell responses are more
40	comparable between the two vaccine technologies [6]. There are relatively fewer studies
41	comparing rates of antibody waning over time, particularly with inactivated vaccines [7, 8].
42	
43	In Hong Kong, two vaccines have been made available to the general public through a mass
43 44	In Hong Kong, two vaccines have been made available to the general public through a mass vaccination program since early 2021, the CoronaVac inactivated virus vaccine (Sinovac)
44	vaccination program since early 2021, the CoronaVac inactivated virus vaccine (Sinovac)
44 45	vaccination program since early 2021, the CoronaVac inactivated virus vaccine (Sinovac) and the BNT162b2 mRNA vaccine ("Comirnaty", BioNTech/Fosun Pharma). As of 11
44 45 46	vaccination program since early 2021, the CoronaVac inactivated virus vaccine (Sinovac) and the BNT162b2 mRNA vaccine ("Comirnaty", BioNTech/Fosun Pharma). As of 11 February 2022, 11.7 million vaccine doses have been administered, with 74% of the
44 45 46 47	vaccination program since early 2021, the CoronaVac inactivated virus vaccine (Sinovac) and the BNT162b2 mRNA vaccine ("Comirnaty", BioNTech/Fosun Pharma). As of 11 February 2022, 11.7 million vaccine doses have been administered, with 74% of the population of about 7.4 million residents receiving at least one vaccine dose, 67% receiving
44 45 46 47 48	vaccination program since early 2021, the CoronaVac inactivated virus vaccine (Sinovac) and the BNT162b2 mRNA vaccine ("Comirnaty", BioNTech/Fosun Pharma). As of 11 February 2022, 11.7 million vaccine doses have been administered, with 74% of the population of about 7.4 million residents receiving at least one vaccine dose, 67% receiving at least two doses, and 16% receiving three doses. Of the 11.7 million doses administered to
44 45 46 47 48 49	vaccination program since early 2021, the CoronaVac inactivated virus vaccine (Sinovac) and the BNT162b2 mRNA vaccine ("Comirnaty", BioNTech/Fosun Pharma). As of 11 February 2022, 11.7 million vaccine doses have been administered, with 74% of the population of about 7.4 million residents receiving at least one vaccine dose, 67% receiving at least two doses, and 16% receiving three doses. Of the 11.7 million doses administered to date, 4.5 million were CoronaVac and 7.2 million were BNT162b2. Here, we followed up

METHODS 53

54 **Recruitment and Follow-up of Participants**

55 We analyzed data from two ongoing community-based cohort studies of infections and

immunity. In the "Evaluating Population Immunity in Hong Kong" (EPI-HK) cohort study 56

57 which was initially designed to study influenza and later also expanded to COVID-19, we 58 enrolled individuals from the community starting in July 2020, and included individuals 59 regardless of COVID-19 vaccination status. For analyses reported here we include the subset 60 of study participants who were aged $\geq 18y$ and have received two doses of COVID-19 vaccination. Blood samples are collected from each participant at approximately six-month 61 intervals, with additional blood samples collected one month after any dose of COVID-19 62 63 vaccination. 64 65 In the "COVID-19 VAccine Research" (COVAR) cohort study which aims to study vaccine immunogenicity and long-term antibody responses in COVID-19 vaccine recipients, we 66

67 enrolled adults ≥18y of age from the general community and from Community Vaccination
68 Centres. In the initial protocol we aimed to enroll individuals shortly before receiving the first

69 dose of any COVID-19 vaccine in Hong Kong, this was later relaxed to allow enrollment of

70 individuals after receiving one or more vaccine doses. Blood samples are collected from each

participant at baseline, one month after any dose of COVID-19 vaccination, and at 6, 12, 24

72 and 36 months after the second dose of vaccination.

73

74 Similar data are collected from participants in both studies, including information on

75 demographics and socio-economic status, underlying medical conditions and regular

76 medication use, and the type and dates of any COVID-19 vaccine doses received. Participants

77 receive coupons worth HK\$100 (approximately US\$13) at each blood draw.

78

79 Ethics

80 Written informed consent was obtained from all participants. The study protocols were

81 approved by the Institutional Review Board of the University of Hong Kong.

82

83 Laboratory Methods

Sera were extracted from the clotted blood samples within 24 hours after collection, divided 84 85 into 2-4 aliquots, and stored at -80°C until subsequent serologic testing. Samples were tested with an ELISA for spike receptor binding domain and a surrogate virus neutralization test 86 87 (sVNT) as previously described [9]. We previously demonstrated that both assays can be 88 used as proxy for neutralizing antibody against SARS-CoV-2 as measured by plaque 89 reduction neutralization test with live virus [10]. 90 91 We obtained sVNT kits from GeneScript USA, Inc, New Jersey and the tests carried out 92 according to the manufacturer's instructions. The % inhibition of each serum was calculated 93 as Inhibition (%) = $(1 - \text{Sample OD value/Negative Control OD value}) \times 100$. Inhibition (%) 94 of \geq 30% was regarded as a positive result while <30% was considered negative [9]. 95

96 ELISA was carried out as previously described [9]. 96-well ELISA plates (Nunc MaxiSorp, 97 Thermo Fisher Scientific) were coated overnight with 100 ng per well of the purified 98 recombinant RBD protein in PBS buffer. The plates were then blocked with 100 µl of 99 Chonblock blocking/sample dilution ELISA buffer (Chondrex Inc, Redmon, US) and 100 incubated at room temperature for 2 h. Each serum or plasma sample diluted 1:100 in 101 Chonblock blocking/sample dilution ELISA buffer was added to duplicate wells and 102 incubated for 2 h at 37°C. After washing with PBS containing 0.1% Tween 20, horseradish 103 peroxidase (HRP)-conjugated goat anti-human IgG (1:5,000, GE Healthcare) was added for 1 104 h at 37°C. The ELISA plates were then washed in PBS with 0.1% Tween 20. Subsequently, 100 µL of HRP substrate (Ncm TMB One; New Cell and Molecular Biotech Co. Ltd, 105 106 Suzhou, China) was added into each well. After 15 min incubation, the reaction was stopped

by adding 50 μL of 2 M H₂SO₄ solution and analyzed on a Sunrise (Tecan, Männedorf,
Switzerland) absorbance microplate reader at 450 nm wavelength. Optical density above 0.5
was considered a positive result.

110

111 Statistical Analysis

112 We assessed mean antibody levels measured by ELISA (optical density, OD) and sVNT (% 113 inhibition) after the first and second dose of COVID-19 vaccination. It was recommended 114 that individuals should receive their second dose 21 and 28 days after the first dose for 115 BNT162b2 and CoronaVac, respectively. We did not include any samples collected after 116 receipt of a third dose, or any samples collected after a confirmed SARS-CoV-2 infection. 117 Differences in antibody levels between vaccine type overall or within each category of age or 118 sex were compared using t-tests. To evaluate the duration after which antibody level fall 119 below the manufacturer's defined sVNT threshold of seropositivity at 30% inhibition 120 (Supplementary Information), we fitted a smoothing spline to antibody levels over time 121 starting at 14 days and up to 180 days after receipt of the second dose. Statistical analyses 122 were conducted using R version 4.1.2 (R Foundation for Statistical Computing, Vienna, 123 Austria).

124

125 **RESULTS**

126 We included data from 2780 vaccinated individuals including 2172 from the EPI-HK study

127 and 608 from the COVAR study who had provided at least one post-vaccination blood

sample by 23 December 2021, contributing 1528 blood samples collected from 799

129 individuals who received CoronaVac (median age 59.4 years, 46.6% male), and 3939 blood

130 samples collected from 1981 individuals who received BNT162b2 (median age 49.3 years,

44.7% male). Additional information on the demographics of study participants is providedin Appendix Table 1.

133

134	Antibody levels increased to moderate levels following two doses of CoronaVac (Figure 1A)
135	compared to very high levels following two doses of BNT162b2 (Figure 1B). The mean
136	sVNT antibody levels measured against ancestral virus at 14-42 days after the second dose
137	for CoronaVac were 53.7% (95% confidence interval, CI: 51.2, 56.3) and for BNT162b2
138	were 94.3% (95% CI: 93.8, 94.7), with significant differences between the two vaccines
139	overall and within each age group (Appendix Table 2). For both vaccines, the observed post-
140	vaccination levels had a slight inverse correlation with age, and average levels were slightly
141	higher in females than in males (p-values <0.01 for these within-group comparisons)
142	(Appendix Table 2). Overall, antibody levels remained below the threshold of 30% after the
143	second dose in 23% and 0.5% of participants who received CoronaVac and BNT162b2,
144	respectively. In particular, the antibody levels did not reach the threshold of 30% in 51% of
145	older adults ≥ 60 years old who received CoronaVac vaccination.
145 146	older adults ≥ 60 years old who received CoronaVac vaccination.
	older adults ≥60 years old who received CoronaVac vaccination. Antibody levels started to decline gradually over time starting from one month after recipient
146	
146 147	Antibody levels started to decline gradually over time starting from one month after recipient
146 147 148	Antibody levels started to decline gradually over time starting from one month after recipient of the second dose for both vaccines, with faster antibody waning in the recipients of
146 147 148 149	Antibody levels started to decline gradually over time starting from one month after recipient of the second dose for both vaccines, with faster antibody waning in the recipients of CoronaVac (Figure 1C and 1D). In recipients of CoronaVac, the fitted curve for average
146 147 148 149 150	Antibody levels started to decline gradually over time starting from one month after recipient of the second dose for both vaccines, with faster antibody waning in the recipients of CoronaVac (Figure 1C and 1D). In recipients of CoronaVac, the fitted curve for average antibody level fell below the threshold of 30% by around 4 months after second dose, while
146 147 148 149 150 151	Antibody levels started to decline gradually over time starting from one month after recipient of the second dose for both vaccines, with faster antibody waning in the recipients of CoronaVac (Figure 1C and 1D). In recipients of CoronaVac, the fitted curve for average antibody level fell below the threshold of 30% by around 4 months after second dose, while remaining elevated for at least six months in recipients of BNT162b2. Consistently, we
 146 147 148 149 150 151 152 	Antibody levels started to decline gradually over time starting from one month after recipient of the second dose for both vaccines, with faster antibody waning in the recipients of CoronaVac (Figure 1C and 1D). In recipients of CoronaVac, the fitted curve for average antibody level fell below the threshold of 30% by around 4 months after second dose, while remaining elevated for at least six months in recipients of BNT162b2. Consistently, we continued to observe significant differences in antibody levels 4-6 months after vaccination

Specifically, sVNT antibody levels fell to below the threshold of 30% in 84% of participants who received CoronaVac, versus none among those who received BNT162b2. However, with a smaller sample size here we were not able to identify statistically significant differences by age or sex within each vaccine group. We also examined antibody levels by ELISA, finding similar comparative patterns of boosting and waning between the two vaccine types (Appendix Figure 1).

162

163 **DISCUSSION**

164 Evidence on antibody boosting and waning after vaccination is important as it affects the 165 potential timing of subsequent booster vaccine doses. Here, we demonstrate higher levels of 166 antibody to SARS-CoV-2 following two doses of the mRNA vaccine BNT162b2 compared 167 to two doses of the inactivated vaccine CoronaVac [5, 6], and longer durability of responses 168 for BNT162b2 for at least six months following the receipt of a second dose [7, 11]. Our 169 finding of rapid waning of antibody following receipt of CoronaVac echoes previous reports 170 [7, 11] and indicates that a third dose would likely be needed sooner, and indeed in Hong 171 Kong third doses have been recommended at ≥ 3 months after the second dose of CoronaVac. 172 It is important to recognize, however, that protection against severe COVID could be retained even in spite of waning of protection from infection [12]. 173

174

We found stronger responses to two doses of both vaccines in females and in younger adults, consistent with other studies. For example Uwamino et al reported similar observations in a cohort of 673 recipients of BNT162b2 [13], while Xu et al. reported stronger and more durable antibody responses in females and younger recipients of an inactivated vaccine [14]. There are a number of potential underlying biological mechanisms that could lead to a sex

180 difference, and stronger antibody responses in women have been reported for other vaccines181 [15].

182

183	There are a number of limitations of our study. First, we did not measure neutralizing
184	antibody against live SARS-CoV-2 but used a surrogate neutralization assay which has a high
185	correlation with live virus neutralization titers [16]. We did not assess antibodies against
186	variants such as Delta or Omicron, but expect antibody levels to be reduced against variants
187	as reported in other studies [16, 17]. We did not assess T cell responses which could
188	contribute to protection against severe disease and could be less affected by variants [18].
189	
190	In conclusion, we identified weaker boosting and faster waning of antibodies against SARS-
191	CoV-2 in recipients of CoronaVac compared to BNT162b2, and would expect this to
192	correlate with lower levels of protection against symptomatic infection for CoronaVac. In
193	individuals of any age or sex, BNT162b2 responses were stronger and more durable than
194	responses to CoronaVac. The weaker and less durable responses following CoronaVac
195	support earlier provision of third doses to persons who previously received two doses of this
196	vaccine.
107	

197

199 ACKNOWLEDGMENTS

200	We acknowledge colleagues including Jemmi Ho, Joyce Lau, Shadow Lau, Leslie Leung
201	(EPI-HK study), Alex Chan, Vincent Fung, Raina Kwan, Lilly Wang, Benny Wong (COVAR
202	study) and other part-time colleagues for technical support in preparing and conducting this
203	study and enrolling participants; Anson Ho for setting up the database; Leo Luk, Karl Chan,
204	John Li, Yonna Leung, Leo Tsang and Zacary Chai for laboratory support; Hetti Cheung,
205	Victoria Wong, Bobo Yeung at HKU Health System; and King-man Ho, Cindy Man and
206	other colleagues at the Community Vaccination Centres at Ap Lei Chau Sports Centre,
207	Gleneagles Hospital and Hong Kong Central Library for facilitating the two cohort studies.
208	
209	FINANCIAL SUPPORT
210	This project was financially supported by the Health and Medical Research Fund of the Food
211	and Health Bureau of the Hong Kong SAR Government (project nos. COVID1903001 and
212	COVID190126), the Theme-based Research Scheme (project no. T11-712/19-N) from the
213	Research Grants Council from the University Grants Committee of Hong Kong, and the
214	Wellcome Trust (grant number: 221013/Z/20/Z). BJC is supported by an RGC Senior
215	Research Fellowship (grant number: HKU SRFS2021-7S03).
216	
217	POTENTIAL CONFLICTS OF INTEREST
218	BJC consults for AstraZeneca, Fosun Pharma, GSK, Moderna, Pfizer, Roche and Sanofi
219	Pasteur. The authors report no other potential conflicts of interest.

221 **REFERENCES**

- 1. Wouters OJ, Shadlen KC, Salcher-Konrad M, et al. Challenges in ensuring global access to
- 223 COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet **2021**;
- 224 **397:1023-34**.
- 225 2. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly
- 226 predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med **2021**;
- 227 27:1205-11.
- 3. Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and
- asymptomatic SARS-CoV-2 infection. Nat Med **2021**; 27:2032-40.
- 4. Earle KA, Ambrosino DM, Fiore-Gartland A, et al. Evidence for antibody as a protective
- correlate for COVID-19 vaccines. Vaccine **2021**; 39:4423-8.
- 232 5. Lim WW, Mak L, Leung GM, Cowling BJ, Peiris M. Comparative immunogenicity of
- 233 mRNA and inactivated vaccines against COVID-19. Lancet Microbe 2021; 2:e423.
- 6. Mok CKP, Cohen CA, Cheng SMS, et al. Comparison of the immunogenicity of
- 235 BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong. Respirology 2021.
- 236 7. Kwok SL, Cheng SM, Leung JN, et al. Waning antibody levels after COVID-19
- 237 vaccination with mRNA Comirnaty and inactivated CoronaVac vaccines in blood donors,
- Hong Kong, April 2020 to October 2021. Euro Surveill 2022; 27.
- 8. Zeng G, Wu Q, Pan H, et al. Immunogenicity and safety of a third dose of CoronaVac, and
- immune persistence of a two-dose schedule, in healthy adults: interim results from two
- single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet
- 242 Infect Dis **2021**.
- 9. Lau EH, Hui DS, Tsang OT, et al. Long-term persistence of SARS-CoV-2 neutralizing
- antibody responses after infection and estimates of the duration of protection.
- 245 EClinicalMedicine **2021**; 41:101174.

- 10. Perera RAPM, Ko R, Tsang OTY, et al. Evaluation of a SARS-CoV-2 Surrogate Virus
- 247 Neutralization Test for Detection of Antibody in Human, Canine, Cat, and Hamster Sera. J
- 248 Clin Microbiol **2021**; 59.
- 249 11. Mok CKP, Cheng SMS, Chen C, et al. A RCT Using CoronaVac or BNT162b2 Vaccine
- as a Third Dose in Adults Vaccinated with Two Doses of CoronaVac. Am J Respir Crit Care

251 Med **2022**.

- 252 12. Tartof SY, Slezak JM, Fischer H, et al. Effectiveness of mRNA BNT162b2 COVID-19
- vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort
- 254 study. Lancet **2021**; 398:1407-16.
- 13. Uwamino Y, Kurafuji T, Sato Y, et al. Young age, female sex, and presence of systemic
- adverse reactions are associated with high post-vaccination antibody titer after two doses of
- 257 BNT162b2 mRNA SARS-CoV-2 vaccination: An observational study of 646 Japanese
- healthcare workers and university staff. Vaccine **2022**.
- 259 14. Xu QY, Xue JH, Xiao Y, et al. Response and Duration of Serum Anti-SARS-CoV-2
- Antibodies After Inactivated Vaccination Within 160 Days. Front Immunol **2021**; 12:786554.
- 261 15. Hussain M, Fatima M, Muhammad Iqbal S, et al. COVID-19 vaccine trials and sex-
- 262 disaggregated data. Expert Rev Vaccines **2021**:1-4.
- 263 16. Cheng SMS, Mok CKP, Leung YWY, et al. Neutralizing antibodies against the SARS-
- 264 CoV-2 Omicron variant following homologous and heterologous CoronaVac or BNT162b2
- 265 vaccination. Nat Med **2022**.
- 266 17. Perez-Then E, Lucas C, Monteiro VS, et al. Neutralizing antibodies against the SARS-
- 267 CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2
- booster vaccination. Nat Med **2022**.
- 269 18. Gao Y, Cai C, Grifoni A, et al. Ancestral SARS-CoV-2-specific T cells cross-recognize
- the Omicron variant. Nat Med **2022**.

271



272

273 Figure 1: Post-vaccination rises followed by longer-term decay in neutralizing antibody levels against the ancestral SARS-CoV-2 virus after receipt of two doses of CoronaVac 274 275 or BNT162b2 vaccination, measured by a surrogate virus neutralization test. Panels A 276 and B show antibody levels prior to receipt of vaccination ("Pre-vaccination"), 14-35 days after receipt of the first dose but no later than the day of receipt of second dose ("After 1st 277 dose"), and 14-42 days after receipt of the second dose ("After 2nd dose"), for an inactivated 278 279 (CoronaVac) or mRNA (BNT162b2) vaccine respectively. Green lines represent mean % 280 inhibition in the respective time periods. Panels C and D show antibody levels between 14-180 days after the receipt of a second dose of CoronaVac or BNT162b2, respectively. Solid 281 282 purple lines represent the spline fit and dotted lines the associated 95% pointwise bootstrap 283 confidence intervals for the estimated changes over time in mean antibody levels. In all four 284 panels, the grey horizontal line indicates the manufacturer's defined threshold for seropositivity at 30% inhibition. 285 286



287

288 Appendix Figure 1: Post-vaccination rises followed by longer-term decay in IgG antibody levels against the ancestral SARS-CoV-2 virus after receipt of two doses of 289 290 CoronaVac or BNT162b2 vaccination, measured by an ELISA assay against the 291 receptor binding domain of the spike protein. Panels A and B show antibody levels prior 292 to receipt of vaccination ("Pre-vaccination"), 14-35 days after receipt of the first dose but no later than the day of receipt of second dose ("After 1st dose"), and 14-42 days after receipt of 293 294 the second dose ("After 2nd dose"), for an inactivated (CoronaVac) or mRNA (BNT162b2) vaccine respectively. Green lines represent mean optical density (OD) in the respective time 295 296 periods. Panels C and D show antibody levels between 14-180 days after the receipt of a 297 second dose of CoronaVac or BNT162b2, respectively. Solid purple lines represent the spline 298 fit and dotted lines the associated 95% pointwise bootstrap confidence intervals for the 299 estimated changes over time in mean antibody levels. In all four panels, the grey horizontal 300 line indicates the manufacturer's defined threshold for seropositivity at OD of 0.5.

302 Appendix Table 1. Characteristics of study participants who received two doses of

303 inactivated vaccine (CoronaVac) or mRNA vaccine (BNT162b2) (n=2780). Participants

from both the EPI-HK and COVAR studies who have antibody levels measured at least once 304

305 between 14-180 days after recipient of the second dose are included.

	vacc (Coron	Inactivated vaccine (CoronaVac) (n=799)		mRNA vaccine (BNT162b2) (n=1981)	
	Number	(%)	Number	(%)	
Age group, years					
18-29	29	(3.6%)	279	(14.1%)	
30-39	43	(5.4%)	346	(17.5%)	
40-49	114	(14.3%)	396	(20.0%)	
50-59	231	(28.9%)	437	(22.1%)	
60-69	284	(35.5%)	419	(21.2%)	
≥70	98	(12.3%)	104	(5.2%)	
Male sex	372	(46.6%)	885	(44.7%)	
Have a clinically-diagnosed chronic condition	235	(29.4%)	412	(20.8%)	
Ever been a regular smoker (of one or more cigarettes a day)	31	(3.9%)	100	(5.0%)	
Interval between first and second vaccination, days					
14-21	3	(0.4%)	1164	(58.8%)	
22-28	564	(70.6%)	704	(35.5%)	
29-35	211	(26.4%)	96	(4.8%)	
36-42	21	(2.6%)	17	(0.9%)	

307 Appendix Table 2. Mean sVNT levels measured against ancestral SARS-CoV-2 virus at

308 14-42 days after the receipt of the second vaccine dose of an inactivated (CoronaVac) or

309 mRNA (BNT162b2) vaccine, overall and by age and sex (n=1431). Only participants from

both the EPI-HK and COVAR studies who have antibody levels measured between 14-42 310

³¹²

Group	Inactivated vaccine (CoronaVac) (n=378)		mRNA vaccine (BNT162b2) (n=1053)		p-value*
	sVNT	(95% CI)	sVNT	(95% CI)	
Overall	53.7	(51.2, 56.3)	94.3	(93.8, 94.7)	< 0.001
Age group, years					
18-29	69.6	(58.8, 80.4)	96.5	(96.2, 96.8)	< 0.001
30-39	54.0	(44.1, 63.9)	94.7	(93.7, 95.6)	< 0.001
40-49	53.1	(46.1, 60.2)	94.4	(93.6, 95.3)	< 0.001
50-59	56.9	(52.5, 61.3)	94.0	(93.2, 94.9)	< 0.001
60-69	51.6	(46.8, 56.4)	93.4	(92.1, 94.6)	< 0.001
≥70	46.3	(38.9, 53.6)	92.3	(89.6, 94.9)	< 0.001
Male	48.0	(43.9, 52.0)	93.3	(92.5, 94.2)	< 0.001
Female	58.6	(55.4, 61.8)	95.0	(94.5, 95.4)	< 0.001

*p-values comparing antibody levels between the two vaccines overall and in each subset of 313

participants (i.e. each row of this table) were estimated by t-tests. 314

315

days after recipient of the second dose are included. 311

317 Appendix Table 3. Mean sVNT levels measured against ancestral SARS-CoV-2 virus at

318 120-180 days after the receipt of the second vaccine dose of an inactivated (CoronaVac)

319 or mRNA (BNT162b2) vaccine, overall and by age and sex (n=134). Only participants

320 from both the EPI-HK and COVAR studies who have antibody levels measured between

³²²

Group	Inactivated vaccine (CoronaVac) (n=51)		mRNA vaccine (BNT162b2) (n=83)		p-value*
	sVNT	(95% CI)	sVNT	(95% CI)	
Overall	21.2	(16.9, 25.6)	81.1	(78.0, 84.3)	< 0.001
Age group, years [†]					
18-39	_††	-	85.8	(80.8, 90.7)	< 0.001
40-59	23.9	(16.1, 31.6)	79.3	(74.3, 84.2)	< 0.001
≥60	18.7	(14.7, 22.8)	78.9	(72.1, 85.7)	< 0.001
Male	16.5	(13.4, 19.7)	80.7	(75.9, 85.6)	< 0.001
Female	24.8	(17.6, 32.0)	81.5	(77.3, 85.7)	< 0.001

323 *p-values comparing antibody levels overall and in each subset between the two vaccines

(i.e. each row of this table) were estimated by t-tests. 324

325 [†]Due to smaller sample sizes we used broader age groups in this analysis compared to the

analysis shown in Appendix Table 2. 326

^{††}Not estimated 327

³²¹ 120-180 days after recipient of the second dose are included.